Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 3 STATUS Data Evaluating SAGE-547 for Super-Refractory Status Epilepticus (SRSE) Due H1 2017 - Originally expected 2nd Half of 2016

Source Link:: http://files.shareholder.com/downloads/AMDA-2RFZJS/3985579166x0x921019/B0716953-8EB2-4D5D-8B6A-E4A1D61969E5/Sage_RD_Day_2016_Final.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

SAGE

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details SAGE announced updated guidance for the expected readout of top-line results for its STATUS Trial (SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus), a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating SAGE-547 as a treatment for patients with super-refractory status epilepticus (SRSE). SRSE is a rare, life-threatening condition of persistent seizure where treatment regimens normally sufficient in stopping seizure activity have failed, and for which there are no approved therapies. Top-line results for the Phase 3 clinical trial are now expected in the second half of 2016.

http://investor.sage...

Additional Relevant Details Top-line Data Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017

http://investor.sage...

Clinical Data Clinical Trial Information

https://clinicaltria...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Sep 12, 2017

Occurred Source:

http://investor.sagerx.com/releasedetail.cfm?ReleaseID=1040009

Related Projects

Digesting the significance of SAGE-547's success in its Phase 2 postpartum depression study SAGE Executed On: Jul 29, 2016 at 12:45 PM EDT

Related Keywords Phase 3 Data, Sage-547, Srse